Amplify Weight Loss Drug & Treatment ETF
THNR
4 hedge funds and large institutions have $1.26M invested in Amplify Weight Loss Drug & Treatment ETF in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
27% more capital invested
Capital invested by funds: $994K → $1.26M (+$266K)
10.44% more ownership
Funds ownership: 20.6% → 31.04% (+10%)
0% more funds holding
Funds holding: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
GTS Securities
New York
|
+$300K |
| 2 |
Jane Street
New York
|
+$225K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$5.53K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HI
Harbour Investments
Madison,
Wisconsin
|
-$66.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GS
1
GTS Securities
New York
| $561K | +$300K | +12,127 | +95% |
|
|
2
Jane Street
New York
| $534K | +$225K | +9,123 | +63% |
|
|
HI
3
Harbour Investments
Madison,
Wisconsin
| $155K | -$66.1K | -2,675 | -28% |
|
|
4
UBS Group
Zurich,
Switzerland
| $10.1K | +$5.53K | +224 | +101% |
|
THNR Hedge Fund Activity: Q4 2024 in Review
4 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Amplify Weight Loss Drug & Treatment ETF (THNR) for Q4 2024, worth a combined $1.26M — up 27% from $994K a quarter earlier.
Fund positioning in THNR was balanced in Q4 2024: 0 funds opened new positions, 0 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was GTS Securities, adding an estimated $300K. The largest seller was Harbour Investments, cutting an estimated $66.1K.
- 4 institutional investors held Amplify Weight Loss Drug & Treatment ETF (THNR) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $1.26M of Amplify Weight Loss Drug & Treatment ETF stock for Q4 2024, up 27% quarter-over-quarter.
- 0 funds opened new Amplify Weight Loss Drug & Treatment ETF positions in Q4 2024 and 0 closed out.
- The largest Amplify Weight Loss Drug & Treatment ETF buyer in Q4 2024 was GTS Securities, an estimated $300K added.
- The largest Amplify Weight Loss Drug & Treatment ETF seller in Q4 2024 was Harbour Investments, an estimated $66.1K sold.
Based on aggregated 13F filings for Q4 2024.